Healthcare -
Biotechnology - NASDAQ - US
$ 0.3875
-11.6 %
$ 17.9 M
Market Cap
-0.65
P/E
1. INTRINSIC VALUE
Balance Sheet
Cellectar Biosciences, Inc.
| Current Assets | 24.3 M |
| Cash & Short-Term Investments | 23.3 M |
| Receivables | 0 |
| Other Current Assets | 962 K |
| Non-Current Assets | 1.22 M |
| Long-Term Investments | 0 |
| PP&E | 1.19 M |
| Other Non-Current Assets | 29.8 K |
| Current Liabilities | 9.39 M |
| Accounts Payable | 611 K |
| Short-Term Debt | 84.4 K |
| Other Current Liabilities | 8.69 M |
| Non-Current Liabilities | 1.79 M |
| Long-Term Debt | 410 K |
| Other Non-Current Liabilities | 1.38 M |
EFFICIENCY
Earnings Waterfall
Cellectar Biosciences, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 51.8 M |
| Operating Income | -51.8 M |
| Other Expenses | -7.2 M |
| Net Income | -44.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cellectar Biosciences, Inc.
| Net Income | -44.6 M |
| Depreciation & Amortization | 292 K |
| Capital Expenditures | -104 K |
| Stock-Based Compensation | 4.27 M |
| Change in Working Capital | -1.73 M |
| Others | -5.97 M |
| Free Cash Flow | -47.7 M |
Wall Street Analysts Price Targets
Cellectar Biosciences, Inc.
CLRB has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CLRB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Cellectar Biosciences, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
8.4 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the entry into definitive agreements to raise $2.5 million from the sale of shares of the company's common stock priced at-market for Nasdaq purposes. The closing of the offering is expected to occur on or about June 6, 2025, subject to satisfaction of customary closing conditions.
globenewswire.com
- 1 week ago
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing Authorization, Answer Expected Late July FLORHAM PARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for iopofosine I 131, a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for the treatment of relapsed/refractory Waldenstrom macroglobulinemia (r/r WM).
globenewswire.com
- 1 week ago
4 Medical Product Stocks to Watch From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
zacks.com
- 3 weeks ago
Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript
Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Jim Caruso - President and CEO Chad Kolean - CFO Jarrod Longcor - COO Anne Marie Fields - IR, Managing Director, Precision AQ Conference Call Participants Aydin Huseynov - Ladenburg Thalmann Operator Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode.
seekingalpha.com
- 1 month ago
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data
globenewswire.com
- 1 month ago
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2025, and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time.
globenewswire.com
- 1 month ago
Cellectar Announces Plan to Explore Strategic Alternatives
FLORHAM PARK, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will explore a full range of strategic alternatives to advance its promising platform and radiopharmaceutical drug development pipeline to maximize stockholder value. Strategic alternatives under consideration may include, but are not limited to mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions. The company's board of directors has approved the engagement of Oppenheimer & Co. Inc. to serve as exclusive financial advisor to assist in the strategic evaluation process.
globenewswire.com
- 1 month ago
4 Medical Product Stocks to Buy From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
zacks.com
- 2 months ago
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?
Here is how Cellectar Biosciences, Inc. (CLRB) and Cencora (COR) have performed compared to their sector so far this year.
zacks.com
- 3 months ago
Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript
Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Anne Marie Fields – Managing Director-Precision AQ Jim Caruso – President and Chief Executive Officer Chad Kolean – Chief Financial Officer Jarrod Longcor – Chief Operating Officer Conference Call Participants Jonathan Aschoff – ROTH Operator Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode.
seekingalpha.com
- 3 months ago
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM)
globenewswire.com
- 3 months ago
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the full year ended December 31, 2024, and provide a corporate update on March 13, 2025, at 8:30 a.m. Eastern Time.
globenewswire.com
- 3 months ago
8. Profile
Summary
Cellectar Biosciences, Inc. CLRB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 17.9 M
Dividend Yield
0.00%
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Contact
100 Campus Drive, Florham Park, NJ, 07932
https://www.cellectar.com
IPO
Date
Nov. 10, 2005
Employees
11
Officers
Mr. Jarrod Longcor
Chief Operating Officer
Mr. James V. Caruso
President, Chief Executive Officer & Director
Mr. Chad J. Kolean CPA
Vice President, Chief Financial Officer & Secretary